SAB Biotherapeutics to Present at UBS Global Healthcare Conference
SAB Biotherapeutics Inc. will present at the UBS Global Healthcare Conference on November 10, 2025, in West Palm Beach, FL. The company is focused on developing human anti-thymocyte immunoglobulin for autoimmune diseases, particularly in delaying type 1 diabetes progression in new onset Stage 3 patients. Management will participate in a fireside chat at 2:45 p.m. ET.
SAB Biotherapeutics Inc. will participate in the UBS Global Healthcare Conference on November 10, 2025, in West Palm Beach, FL. The company, which is developing human anti-thymocyte immunoglobulin for autoimmune diseases and focusing on delaying the progression of type 1 diabetes in new onset Stage 3 patients, will be represented by members of its management team in a fireside chat at 2:45 p.m. ET. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SAB Biotherapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9567844-en) on November 04, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
